{
    "nct_id": "NCT04893486",
    "official_title": "A Multicenter, Phase 2B, Randomized, Double-Blind, Stratified, Vehicle-Controlled Study Evaluating The Safety And Efficacy Of QTORIN 3.9% Sirolimus Topical Gel In Prevention Of BCCs In Patients With Gorlin Syndrome",
    "inclusion_criteria": "* Adults, 18 years or older\n* Meet diagnostic criteria for Gorlin Syndrome\n* Willing to avoid application of a non-study topical medication to the face (prescription or over the counter) during the study.\n* Willing to forego treatment of BCCs with anything other than the study medication except when the Investigator believes that delay of treatment of a BCC potentially might compromise the health of the subject. During the trial, the only allowed form of BCC treatment is surgical.\n* Participant will be encouraged to use their preferred sunscreen with a sun protector factor (SPF) of at least 30 daily\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Recently participated in a clinical trial evaluating an investigational product for the treatment of BCCs or Gorlin Syndrome within 3 months prior to to starting study medication. Participant can start the study screening period prior to completing the 3 month washout.\n* Recently used topical or systemic (oral) treatment that might interfere with the evaluation of the study medication.",
    "miscellaneous_criteria": "Key"
}